Company Profile

Impel Neuropharma Inc (AKA:Impel Biopharmaceuticals)
Profile last edited on: 12/15/22      CAGE: 55Y39      UEI: VGX8L65CX5A3

Business Identifier: Intranasally delivered treatments for CNS disorders
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

201 Elliott Avenue West Suite 260
Seattle, WA 98119
   (206) 568-1466
Location: Single
Congr. District: 07
County: King

Public Profile

Impel NeuroPharma (NASDAQ:IMPL) is a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier (BBB) using direct nose-to-brain delivery. Direct brain delivery may allow for lower dose volumes, decreased systemic exposure and faster onset than traditional delivery routes. The firm's Pressurized Olfactory Delivery (POD) device uses dynamic airflow to deliver therapeutics to the brain via the upper nasal cavity and olfactory epithelium. This region represents a unique pathway to bypass the blood-brain barrier and allow neuro-active compounds and biotechnology products to be readily absorbed into the brain. The device incorporates a safety interlock, is cost-effective to manufacture, comfortable to use, the size of an asthma-inhaler, disposable, composed of medical grade plastics and uses FDA-approved excipients. IThe most recent application organizes around migraines and Parknmson Disease. mpel's pipeline includes analgesics, chemotherapeutics and anti-retrovirals.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2017 2 NIH $2,163,766
Project Title: Tool for Non-Invasive Delivery of Central Nervous System Drug Candidates
2012 1 NIH $149,513
Project Title: Central Nervous System Delivery of Opioid Peptides
2010 2 CBD $847,975
Project Title: Blood Brain Barrier Drug Delivery of Therapeutics for Chemical Warfare Agents
2010 2 NIH $495,245
Project Title: Cns Targeted Delivery of Anti-Hiv Drugs

Key People / Management

  Adrian Adams -- Chairman & CEO

  Michael Hite -- Founder and President

  Sheena K Aurora -- VP of Medical Affairs Ė Migraine

  Jen Berman -- VP of Marketing

  Patty Billingsley -- VP of Sales

  Alan Brunelle -- Director of R&D

  Rigo Canal -- VP of Commercial Operations & Analytics

  Lynn Gold -- Senior VP of Regulatory

  Richard Haiduck -- Chief Business Officer

  Michael Hite -- Co-Founder and Advisor

  Rodney Jy Ho -- Founder

  John Hoekman -- Founder and Chief Technology and Development Officer

  Albie Lavin -- Senior Product Development Engineer

  John Leaman -- Chief Financial Officer

  Michael Malafronte -- VP of Quality Assurance

  Leonard S Paolillo -- Chief Commercial Officer

  Gerald F Penn -- VP of Market Access & Trade

  Sutapa Ray -- Project Manager, Business Development

  Stephen Shrewsbury -- Stephen Shrewsbury Chief Medical Officer

  Scott Youmans -- Senior VP of Technical Operations